Insulin Biosimilars - An Emerging Opportunity in Diabetes Treatment
Its Development The development of biosimilars requires extensive analytical, preclinical and clinical research to demonstrate similarity to the reference product. For insulin, this includes demonstrating comparable pharmacokinetic and pharmacodynamic profiles. Several companies have invested significant resources in developing follow-on versions of major insulin products that have lost patent...
0 Commentarios
0 Acciones